Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking.
COVID-19
/ diagnosis
Case-Control Studies
Female
GTP-Binding Proteins
/ metabolism
Gene Frequency
Genetic Predisposition to Disease
/ genetics
Genotype
Humans
Iran
Male
Middle Aged
Models, Molecular
Molecular Docking Simulation
Polymorphism, Genetic
Protein Binding
Receptor, Cannabinoid, CB2
/ chemistry
SARS-CoV-2
Severity of Illness Index
Journal
Archives of virology
ISSN: 1432-8798
Titre abrégé: Arch Virol
Pays: Austria
ID NLM: 7506870
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
08
05
2021
accepted:
16
07
2021
pubmed:
14
9
2021
medline:
16
10
2021
entrez:
13
9
2021
Statut:
ppublish
Résumé
Evidence supports a role of host genetic diversity in the clinical course of coronavirus disease 2019 (COVID-19). Variation in the cannabinoid CB2 receptor gene (CNR2) could affect the regulatory action of endocannabinoids on the immune system, resulting in an increased risk of various inflammatory diseases. The present study investigated the relationship between the CNR2-Q63R variant and COVID-19 severity. A total of 200 Iranian COVID-19 patients were enrolled in the study and genotyped using a TaqMan assay. The co-dominant, dominant, recessive, over-dominant, and additive inheritance models were analyzed using SNPStats software. In silico molecular docking was also performed to simulate the effects of the Q63R variation on CB2 binding with a ligand and with the G-protein. A significant difference in the Q63R allele and genotype distribution was found between expired and discharged COVID-19 patients in co-dominant, recessive, and additive inheritance models. The molecular docking results showed that the predicted structure of mutant CB2 (63R type) could not bind to the G-protein in the correct position. The data indicated that the Q63R variation in the CNR2 gene may affect the severity of COVID-19. Identification of genes related to susceptibility and severity of COVID-19 may lead to specific targets for drug repurposing or development.
Identifiants
pubmed: 34514519
doi: 10.1007/s00705-021-05223-7
pii: 10.1007/s00705-021-05223-7
pmc: PMC8435402
doi:
Substances chimiques
CNR2 protein, human
0
Receptor, Cannabinoid, CB2
0
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3117-3126Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Int J Mol Sci. 2020 May 27;21(11):
pubmed: 32471272
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Nature. 2021 Mar;591(7848):92-98
pubmed: 33307546
Nat Rev Neurosci. 2003 Nov;4(11):873-84
pubmed: 14595399
Bioinformatics. 2006 Aug 1;22(15):1928-9
pubmed: 16720584
J Epidemiol Community Health. 2005 Mar;59(3):186-92
pubmed: 15709076
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Med Virol. 2020 Sep;92(9):1511-1517
pubmed: 32437052
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
J Mol Neurosci. 2020 Jan;70(1):26-31
pubmed: 31407233
Clin Rheumatol. 2018 Nov;37(11):2933-2938
pubmed: 30032418
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Nat Protoc. 2015 Jun;10(6):845-58
pubmed: 25950237
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Respir Med. 2021 Apr-May;180:106356
pubmed: 33713961
Toxicol Sci. 2013 Feb;131(2):419-33
pubmed: 23152191
J Microbiol Immunol Infect. 2020 Jun;53(3):425-435
pubmed: 32414646
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):416-418
pubmed: 32271726
J Leukoc Biol. 2011 Nov;90(5):983-95
pubmed: 21873455
Biophys J. 2011 Nov 16;101(10):2525-34
pubmed: 22098752
Blood Coagul Fibrinolysis. 2013 Apr;24(3):247-51
pubmed: 23406660
Nat Protoc. 2010 Apr;5(4):725-38
pubmed: 20360767
Curr Top Behav Neurosci. 2009;1:37-63
pubmed: 21104379
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Virulence. 2018 Jan 1;9(1):217-230
pubmed: 28992427
J Mol Biol. 1963 Jul;7:95-9
pubmed: 13990617
Biol Psychiatry. 2016 Apr 1;79(7):516-25
pubmed: 26698193
Haematologica. 2011 Dec;96(12):1883-5
pubmed: 21828121
Nucleic Acids Res. 2017 Jul 3;45(W1):W365-W373
pubmed: 28521030
Twin Res Hum Genet. 2020 Dec;23(6):316-321
pubmed: 33558003
J Med Virol. 2016 Jan;88(1):1-12
pubmed: 26059175
J Clin Gastroenterol. 2018 May/Jun;52(5):e37-e43
pubmed: 27875353
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Immunol Today. 1998 Aug;19(8):373-81
pubmed: 9709506
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Mol Ther Methods Clin Dev. 2020 May 22;18:1-6
pubmed: 32537478
Pharmacogenet Genomics. 2010 Mar;20(3):157-66
pubmed: 20124950
Biochim Biophys Acta. 2002 Jul 19;1576(3):255-64
pubmed: 12084572
Scand J Rheumatol. 2015;44(4):284-7
pubmed: 25974389
Expert Rev Respir Med. 2020 Apr;14(4):415-423
pubmed: 31995408
J Leukoc Biol. 2008 Mar;83(3):785-96
pubmed: 18073275
Expert Rev Respir Med. 2020 Sep;14(9):881-888
pubmed: 32536226
Viral Immunol. 2018 May;31(4):292-298
pubmed: 29461930
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Epidemiol Infect. 2006 Apr;134(2):223-30
pubmed: 16490124
Immunobiology. 2010 Aug;215(8):598-605
pubmed: 19457575
Genet Test Mol Biomarkers. 2018 May;22(5):320-326
pubmed: 29694791
Bioinformatics. 2016 Dec 1;32(23):3676-3678
pubmed: 27503228
J Leukoc Biol. 2005 Jul;78(1):231-8
pubmed: 15845647
Pharmacol Res. 2012 Jul;66(1):88-94
pubmed: 22465144
Expert Rev Respir Med. 2020 Oct;14(10):965-967
pubmed: 32576053